Pathologic testing for ALK and ROS1 aberrations in NSCLC | Frédérique Penault-Llorca

Frédérique Penault-Llorca outlines the importance of the ALK and ROS1 driver alterations in NSCLC and the available methods for their detection. View more on Medicine Matters oncology: https://bit.ly/3Jnn45m

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.